Figure S1. The expression and mutational profile of AURKA pan-cancer. (A) The expression and (B) mutational profile of AURKA is shown in several types of cancer based on data obtained from TIMER2.0 website. *P<0.05, **P<0.01 and ****P<0.001. AURKA, Aurora kinase A.



BLCA

BRCA-LumB

BRCA-Her2

BRCA

LUSC

BRCA-LumA

LGG

COAD

HNSC-HPV-

HNSC

Figure S2. AURKA overexpression promotes esophageal squamous cell carcinoma cell proliferation and colony formation. KYSE450, KYSE30 and KYSE150 cells were transiently transfected with empty vector or an AURKA overexpression plasmid. (A) The overexpression efficiency of AURKA was detected by western blotting. (B and C) Cell proliferation was measured following AURKA overexpression by (B) MTT and (C) soft agar colony formation assays. *P<0.05, **P<0.01 and ***P<0.001. AURKA, Aurora kinase A.



Figure S3. AURKA-interacting proteins screening using pull down assays. (A) AURKA protein was purified and stained with CBB. (B) Purified AURKA protein was detected by western blotting. (C) Purified AURKA protein was incubated with or without KYSE410 cell lysates and was subjected to a histidine-pull-down assay. The precipitated proteins were stained with CBB. (D) KYSE410 cell lysates were immunoprecipitated with an anti-AURKA antibody and then immunoblotted with the indicated antibodies. AURKA, Aurora kinase A; CBB, Coomassie brilliant blue.







Figure S5. Correlation between AURKA or TPX2 expression with the infiltration of CD4+ T cell subsets. (A and B) The relationship between (A) AURKA or (B) TPX2 expression with the infiltration of CD4+ T cell subsets was obtained from the TIMER2.0 database. AURKA, Aurora kinase A.

